February 2018
NCI Standard Funding Opportunity Announcements | |||||||||||||||||||
| Current and Recent Program Announcements | Current and Recent Requests for Applications | |||||||||||||||||||
|
Current
and Recent NCI and Trans-NIH Initiatives |
Requests for Proposals
|
Standard Due Dates |
|||||||||||||||||||
 Updated |
Army Research Office (ARO) Broad Agency Announcement (BAA)
The purpose of this BAA is to solicit research proposals in the
engineering, physical, life, and information sciences for
submission to the Army Research Office (ARO) for consideration
for possible funding. Whitepapers and proposals will be
evaluated only if they are for fundamental scientific study and
experimentation directed toward advancing the scientific state
of the art or increasing basic knowledge and understanding.
| ||||||||||||||||||
| Due Dates: | Open until Mar. 31, 2022 Proposers are to submit white papers prior to submission of a complete proposal. Based on assessment of white papers, feedback will be provided to encourage or discourage submission of full proposals. |
| Amount & Project Period: | No specific dollars have been reserved - 3 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research - (x6804) |
| Link: | Funding Opportunities - Open Broad Agency Announcements (BAA) |
| Open | All Ranks | Non-federal | Clinical Trials |
The Gateway for Cancer Research
Research Grants
Gateway focuses on transformational science via effective
clinical trials - when basic science translates into human
testing and clinical practice. | Due Dates: | Rolling requests for funding conducted in two stages: a Letter of Intent (LOI) and if invited, a full application. Applicants must submit via Gateway's Grant Management System |
| Amount & Project Period: | Funding is variable and duration is 1 to 3 years |
| Eligibility: | All Ranks |
| Contact: | Gateway Contacts are: Jerian Dixon-Evans, Research Grants Specialist Jerian.Dixon-Evans@gatewaycr.org (847) 342-7361 and Domarina Oshana, Ph.D., Director of Research and Grants Domarina.Oshana@gatewaycr.org (847) 342-7443 |
| Link: | Grant Application Process |
NEW
| January 19 (LOI) | All Ranks | Non-federal | Health Disparities |
Florida Department of Health
Office of Minority Health and Health Equity
Reducing Racial and Ethnic Health Disparities
Closing the Gap Grant Program (CTG)
RFA #: 17-007
The CTG Grant Program seeks to promote improvement of minority
health outcomes and elimination of health disparities through
development of closely coordinated community-based and
neighborhood-based projects. This RFA seeks applications that
will improve health outcomes of racial and ethnic populations by
proposing evidence-based disease prevention and intervention
strategies, by creating sustainable partnerships and by
mobilizing communities to support long- term social change.
Provision of medical or clinical services is not permitted under
this funding.| Due Dates: | January 19 (Letter of Intent w/Area of Intervention must be emailed to: OMHCTGDatabase@flhealth.gov by 5pm EST Applications Due: Feb. 14 (OSR) - Feb. 16 (Sponsor - receipt date) |
| Amount & Project Period: | Max. $200,000, Average award $150,000) - 1
year CTG grants shall be awarded on a matching basis. The matching funds requirement is that one dollar cash in local (non-state) matching funds must be provided for each three-dollar grant payment made by the state, with certain exceptions listed in the RFA (1.7 Matching Funds Requirement) |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Closing the Gap RFA 17-007 | DOH/OMHHE/Closing the Gap |
NEW
| January 19 | Fellows | Non-federal | Health Policy Fellowship Program |
American Society of Clinical Oncology (ASCO)
Health Policy Fellowship
Program
ASCO's Health Policy Fellowship program aims to provide U.S.-based
oncologists with the necessary skills to shape cancer policy and
help increase involvement of ASCO members in policy, advocacy
and grassroots activity. ASCO is actively recruiting oncologists
who have a keen interest in acquiring stronger health policy
skills and have the leadership, civic, policy, or advocacy
experience for this year-long program. | Due Dates: | Jan. 17 (OSR) - Jan. 19 (Sponsor) |
| Amount & Project Period: | Requires 1-year commitment to include regular travel to ASCO, estimated at one week each month. The home institution is expected to cover full salary and benefits for duration of fellowship. ASCO will cover all travel to ASCO and living expenses while Fellow is working on site at ASCO or traveling as required by the program. |
| Eligibility: | Applicants must meet the following criteria:
Physicians (MD, DO or international. Equiv.); Based in U.S. practice or institution; Completed at least 2 years clinical oncology training; ASCO members (full member or member in training); U.S. Citizens or Permanent Residents ASCO strongly encourages application submissions from all oncology subspecialties. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Health
Policy Fellowship ASCO's Grants Portal Call for Applications |
| R25 | NCI |
| January 25 | All Ranks | Federal | Cancer Education/Curriculum/Methods Development |
Cancer Research Education Grants Program - Curriculum or Methods Development
The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.| Due Dates: | Jan. 23 (OSR) Ι Jan. 25 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | $150,000/yr. (Direct Costs) - 2 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-476 |
| Companion FOAs: |
PAR-18-477, R25 (Courses for Skills Development) PAR-18-478, R25 (Research Experiences) |
| January 26 (Pre-application) | All Ranks | Federal | Applied Science |
Defense Health Program
Congressionally Directed Medical Research Programs
FY17-18 Defense Medical Research and Development Program (DMRDP)
Accelerating Innovation in Military Medicine Research Award
(AIMM)
The AIMM initiative supports applied
research that utilizes systematic studies to understand the
means to meet a recognized and specific need...Applied research
may include hypothesis-testing and/or proof-of-concept studies
as well as work that refines concepts and ideas into potential
solutions with a view toward evaluating technical feasibility of
emerging approaches, technologies, and promising new products.
| Due Dates: | Jan. 26 (Pre-application) Feb. 07 (OSR) Ι Feb. 09 (Sponsor) |
| Amount & Project Period: | $350,000 (Direct Costs) - 18 months |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: |
W81XWH-17-DMRDP-AIMM General Submission Instructions |
| January 29 (LOI) | Junior faculty | Non-federal | Career Development |
American Thyroid Association (ATA)
ATA Call for Research
Grants
Funds available to support new investigator initiated
research projects in the area of thyroid function and disease.
Topics may include, but are not limited to, Clinical Disorders
of Thyroid Function, Thyroid Autoimmunity, Thyroid Cancer,
Thyroid Hormone Effect and Metabolism, and Thyroid Imaging.| Due Dates: | Jan. 29 (Letter of Intent) Invited Submissions: April 2018 |
| Amount & Project Period: | $25,000/yr. (Direct Costs) - 2 years |
| Eligibility: | Must be new
investigators <6 years from completion of post-doctoral
fellowship and not been PI on an NIH RO1 or equiv. grant (recipients of
NIH R29, R21 and KO8 awards are eligible);
Postdocs are eligible if department provides written
confirmation that at time of award applicant will have a junior faculty
position; Must be ATA member or apply for complimentary membership by April 2018 |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | ATA 2018 Research Grants Ι Call for Research Grants Proposals |
| January 29 | All Faculty Ranks | Non-federal | Brain Tumors |
Southeastern Brain Tumor Foundation
2018 Research Grant Cycle
SBTF grant awards are viewed as seed funding for continued development of
promising research programs, and support potential advances in
technologies and clinically-viable treatments for brain tumors.
Seed funding from SBTF will foster the continued development of
emerging concepts, treatments and therapies so that researchers
working in the area of brain tumors can garner national
recognition and funding from larger funding agencies, such as
the American Cancer Society or National Institutes of Health.
| Due Dates: | Jan. 25 (OSR) Ι Jan. 29 (Sponsor) |
| Amount & Project Period: | Up to $75,000 - 1 year |
| Eligibility: | All Faculty Ranks (Research Associates and
individuals holding equiv. non-faculty level positions are not
eligible.) Grants are limited to pre-clinical research and clinical trials |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | 2018 Guidelines and Instructions Ι 2018 SBTF FAQs |
| U01 | NCI |
NEW
| January 30 (LOI) | NCI U01 Awardees | Federal | NCI-supported Technology |
Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (Clinical Trial Optional)
The purpose is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects proposing to expand upon original research question(s) or otherwise accelerate progress for parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.| Due Dates: | Jan. 30 (Letter of Intent, not required, or
binding) Feb. 26 (OSR) Ι Feb. 28 (Sponsor) Additional 2018 Due Dates: May 29 and Sept. 28 |
| Amount & Project Period: | Not to exceed $150,000/yr. (Direct Costs) - up to 2 years, not to exceed remaining number of years on parent grant. If a no-cost extension is needed on parent grant, it must be in place before the revision application is submitted. |
| Eligibility: | All Ranks - Revision applications from active NCI U01 awardees |
| Contact: | Office of Sponsored Research (x6804) |
| RFA Link: | RFA-CA-18-007 |
| Companion RFAs: |
RFA-CA-18-006, R01 Research Project Grant RFA-CA-18-009, P01 Program Project Grant RFA-CA-18-008, P50 Research Project - Cooperative Agreements RFA-CA-18-010, U54 Resource-Related Research Projects - Cooperative Agreements |
| January 31 | All Ranks | Non-federal | Pancreatic |
The National Pancreas Foundation
2018 Research Grants & Awards
Research must be in the field of pancreatic diseases. Studies intended to
advance knowledge in the areas of pancreatic carcinoma, and all
forms of pancreatitis would be the closest to the areas of
interest.| Due Dates: | Jan. 29 (OSR) Ι Jan. 31 (Sponsor) |
| Amount & Project Period: | $50,000 - 1 year |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research - (x6804) |
| Link: | 2018 Research Grants & Awards |
| January 31 | All Ranks | Non-federal | Sarcoma |
Sarcoma Foundation of America
Research Grant
This program provides grants to investigators interested in
translational science sarcoma research The Foundation will only
accept applications that focus on the following areas of
research: Omic characterization of sarcomas and definition of novel targets;
Omic patterns of sensitivity and resistance to existing agents;
Systemic therapy combinations;
Immunotherapy
| Due Dates: | Jan. 27 (OSR) Ι Jan. 31 (Sponsor) |
| Amount & Project Period: | $50,000 - 1 year |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Apply for a Grant Ι proposalCENTRAL (Submission Site) |
NEW
| February 01 (LOI) | Full Members | Non-federal | Research Support |
American Cancer Society (ASC)
Research Professor Awards
This
award provides Flexible support for established investigators in
mid-career who have made pioneering contributions that have
changed the direction of cancer research. It is expected that
these investigators will continue to provide leadership in their
research area. An ACS Research Professor is required to be a
spokesperson for the ACS and for cancer research.| Due Dates: | Feb. 01 (Letter of Intent) Invited Application: Mar. 29 (OSR) | Apr. 01 (Sponsor) |
| Amount & Project Period: | $400,000 - 5 years |
| Eligibility: | Applicants will
have attained rank of full professor or equiv. and must not
have held this rank for more than 15 years; Awardee will accept role of speaking on behalf of the American Cancer Society and using the title as appropriate in professional appearances and publications. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
Research Professor Grants proposalCENTRAL (LOI and Application Submission) |
NEW
| February 01 | Junior Faculty | Non-federal | All Cancer Research |
The AAAS Martin and Rose Wachtel Cancer Research Award
Applications are invited for this annual award that honors early-career investigators who have performed outstanding work in the field of cancer research.| Due Dates: | Feb. 01 (Sponsor Receipt Date) |
| Amount & Project Period: | Award winner(s) receive a cash award of $25,000 and are invited to deliver a public lecture on their research. The award-winning Essay(s) will be published in Science Translational Medicine. |
| Eligibility: | Entrant must have
received Ph.D. or M.D. w/in last 10 years; Research must have been performed during previous 10 years. Entrant must have performed or personally directed work described in Essay. |
| Contact: | Send inquiries by email to wachtelprize@aaas.org |
| Link: | Overview & Submission Guidelines |
| February 01 | Postdocs | Non-federal | Career Development |
Jane Coffin Childs Memorial Fund for Medical Research (JCC)
Fellowship Awards
The JCC supports research into causes and treatment of cancer,
with a broad approach to the study of cell growth and
development, emphasizing the study of the basic biology and
chemistry of the underlying processes.| Due Dates: | Jan. 30 (OSR) Ι Feb. 01 (Sponsor) |
| Amount & Project Period: | Basic stipend: $52,000/year 01; $52,500/year 02; and $53,000/year 03 Additional $1,000 per dependent child; Allowance $2,000/year for research; costs to sponsoring laboratory; may not be used for travel. |
| Eligibility: | Postdoctoral
applicants should have < 1 year of postdoctoral research
experience at application deadline; PhD. degree must not have been conferred more than 18 months prior to the deadline date; MD. degree should not have been conferred > 3years before deadline date; PhD. candidates without a degree at application deadline are eligible to apply. However, if awarded, PhD. degree must be conferred prior to start of Fellowship. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Fellowship Information Ι Dates and Documents |
| February 01 | All Ranks | Non-federal | Lung Cancer in Women |
A Breath of Hope Lung Foundation
Lung Cancer in Women
This award will be focused on understanding ling cancer in
women. The goal is to fund translational projects that will
evolve into clinical trials within five years. The Foundation
is also open to funding new pathways for disease diagnosis and
treatment discovery.
| Due Dates: | Jan. 30 (OSR) Ι Feb. 01 (Sponsor) Note that eligibility must be confirmed in order to receive a link to the online application. |
| Amount & Project Period: | $150,000 - 2 years |
| Eligibility: | All Ranks - Must have M.D., M.D. /Ph.D., PhD, D.O., DrPH or MS. |
| Contact: | Office of Sponsored Research - (x6804) |
| Links: | Tona Vives Research Award Ι Eligibility Confirmation |
| February 01 | All Faculty Ranks | Moffitt | See Guidelines |
Innovative Studies Funding Opportunity (Cycle 2)
Moffitt invites its investigators to apply for grant funding to address unmet medical needs or standard of care challenges.| Due Dates: | Jan. 29 (OSR) Ι Feb. 01 (OSR will submit to Alliance Management Dept.) |
| Amount & Project Period: | $870,000 (direct costs) for up to 2 years (i.e., either $870,000 for 1 year or $435,000/yr. for 2 years) |
| Eligibility: | All Faculty Ranks |
| Contact: | Alliance Management Department |
| Link: | Guidelines |
| February 01 | All Ranks | Federal | PCOR/Meeting Support |
Patient Centered Outcomes Research Institute (PCORI)
Engagement Award (EAIN): Research Meeting and Conference
Support
This initiative can provide funding support for meetings and
conferences that align with the PCORI's Mission and
Strategic Plan and facilitate expansion of patient-centered
outcomes research/comparative clinical effectiveness
research (PCOR/CER). Please note that the Application Guidelines have changed as of June 2, 2017.
| Due Dates: | Jan. 30 (OSR) Ι Feb 01 (Sponsor) |
| Amount & Project Period: | $50,000 total costs -1 year |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Opportunity Summary Ι EAIN Guidelines |
| February 01 (LOI) | Junior Faculty | Non-federal | Career Development/Blood Cancers |
Leukemia Research Foundation
Hollis Brownstein Research Grant Program for New
Investigators
This program allows innovative scientists to act
on their ideas, and try new procedures and experiments that will
hopefully lead to significant breakthroughs. Preference given to
proposals focusing on leukemia, lymphoma, MDS, and multiple
myeloma.
| Due Dates: | Feb. 01 (Letter of Intent) Invited Submissions: Mar. 13 (OSR) Ι Mar. 15 (Sponsor) |
| Amount & Project Period: | $100,000 (Total Costs) -1 year |
| Eligibility: | New Investigators
are considered to be w/in 7 years of first independent position.
Years as a resident physician, fellow physician, or post-doctoral fellow
are considered to be training years; Investigators at instructor level or similar position must include a letter from department chair confirming applicant's independence; Applicants with an NIH KO8 or K23 are eligible. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
Hollis Brownstein Research Grants Program Guidelines Application Information |
| February 02 | Female Postdocs | Non-federal | Career Development |
L'Oreal USA For Women In Science and American
Association for the Advancement of Science
The L'Oreal USA for Women in Science Fellowship Program
This program rewards women postdoctoral scientists for their
contributions in Science, Technology, Engineering and Math
(STEM) fields and commitment to serving as role models for
younger generations. L'Oréal USA partners with the American
Association for the Advancement of Science (AAAS) to manage the
program's application and peer-review process.
| Due Dates: | Jan. 31 (OSR) Ι Feb. 02 (Sponsor) |
| Amount & Project Period: | $60,000 - 1 year |
| Eligibility: | Must hold PhD and
have started in a postdoctoral research position by February
2, 2018 and maintain status throughout fellowship year; Must be American born, naturalized citizen or permanent resident; See announcement for additional requirements. |
| Contact: | Office of Sponsored Research - (x6804) |
| Links: | About the Program Ι L'Oreal USA For Women In Science |
| R01 | NIH |
Parent R01 for investigator-initiated projects
| February 05 | All Ranks | Federal | Research Project Grants |
NIH Research Project Grant (Parent R01 Clinical trial not Allowed)
The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.| Due Dates: | Standard dates apply This FOA must be used for applications submitted after January 25, 2018 |
| Amount & Project Period: | Application budgets are not limited - max. 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research - (x6804) |
| FOA Link: | PA-18-484 |
| R01 | NIH |
| February 05 | All Ranks | Federal | Education & Health Outcomes |
Education and Health: New Frontiers (Clinical Trial Optional)
The goal is to support research that will further elucidate pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship.| Due Dates: | Feb. 01 (OSR) Ι Feb. 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Application budgets not limited - 2 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-387 |
| Companion FOAs: |
PAR-18-362 R21 -
Standard Due Dates apply PAR-18-388 R03 - Standard Due Dates apply |
| R01 | NCI |
NCI R01 Reminder
| February 05 | All Ranks | Federal | See Specific FOA |
National Cancer Institute "R01" New/Renewed Funding Opportunity Announcements (FOAs)
Listed below are a few new and renewed R01 funding opportunities from NCI, as well as a link to the full listing of active FOAs.| Due Dates: | Feb. 01 (OSR) Ι Feb. 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Generally budgets are not limited and the maximum performance period is 5 years, but FOAs will state amount and time period. |
| Eligibility: | All Ranks, unless restricted in specific FOA |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Links: |
Using Information Technology to Support Systematic Screening and
Treatment of Depression in Oncology Practices (R01 Clinical Trial
Optional)
PA-18-493 Early-life Factors and Cancer Development Later in Life (R01 - Clinical Trial Not Allowed)PA-18-529 Metabolic Reprogramming to Improve Immunotherapy PAR-16-228 See full list at 2018 Program Announcements (PAs) |
| R01 | NIH |
NEW
| February 05 | All Ranks | Federal | Pain Therapy |
Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (Clinical Trial Optional)
The purpose is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain. For NCI: The role of cannabinoids and the endocannabinoid system in treatment of metastatic bone pain, chemotherapy induced peripheral neuropathy, and aromatase inhibitor arthralgias.| Due Dates: | Feb. 01 (OSR) Ι Feb. 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-465 |
| R01 | NIH |
NEW
| February 05 | All Ranks | Federal | Geriatric Palliative Care |
Advancing the Science of Geriatric Palliative Care (Clinical Trial Optional)
The purpose is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain. For NCI: The role of cannabinoids and the endocannabinoid system in treatment of metastatic bone pain, chemotherapy induced peripheral neuropathy, and aromatase inhibitor arthralgias.| Due Dates: | Feb. 01 (OSR) Ι Feb. 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-502 |
| Companion FOA: | PA-18-503 (R21) (Due Date: 2/16) |
| R01 | NIH |
| February 05 | All Ranks | Federal | HIV/Aids & Aging |
Multidisciplinary Studies of HIV/AIDS and Aging (Clinical Trial Optional)
This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science.NCI seeks research studies to help understand how aging in the presence of chronic HIV infection affects the risk, spectrum and biology of cancer (AIDS-defining and non-AIDS-defining cancers).
| Due Dates: | Feb. 01 (OSR) Ι Feb. 05 (Sponsor) Additional Due dates: Standard dates |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-189 |
| Companion FOA: | PAR-18-190 R21 Clinical Trial Optional (Due Date: 2/16) |
| R01 | NIH |
| February 05 | All ranks | Federal | Population Health |
Population Health Interventions: Integrating Individual and Group Level Evidence (Clinical Trials Not Allowed)
The purpose is to support multilevel, transdisciplinary population health interventions targeting underlying social, economic, and environmental conditions in an effort to improve health outcomes. NCI encourages applications designed to study multi-level interventions aimed at improving cancer prevention and control along any aspect of the cancer control continuum. (See detailed NCI information in Part 2, Section 1 of the FOA).| Due Dates: | Feb. 01 (OSR) Ι Feb. 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Application budgets not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-356 |
| Companion FOAs: |
PA-18-406 R21 - Clinical Trials not allowed PA-18-385 R01 - Clinical Trial Optional PA-18-407 R21 - Clinical Trial Optional Standard Due Dates apply for all |
| R01 | NIH |
| February 05 | All Ranks | Federal | Behavioral & Social factors in Health and Disease |
Methodology and Measurement in the Behavioral and Social Sciences (R01 Clinical Trial Optional)
The participating NIH Institutes and Centers (ICs) encourage research that will improve the quality and scientific power of behavioral and social science data relevant to the IC missions. Applicants are strongly encouraged to contact the Scientific/Research Contact (listed in Section VII of the FOA) for the IC that most closely matches the research focus to determine IC interest in the proposed research topic.| Due Dates: | Feb. 01 (OSR) Ι Feb. 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Application budgets not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-352 |
| Companion FOA: | PAR-18-378, R21 (Due Feb. 16) |
| "K" Awards | NCI |
NCI K Award Reminder
| February 12 | All Ranks | Federal | Career Development |
National Cancer Institute "K" Awards
The purpose of the "K" Awards is to provide opportunities for mentored and non-mentored career development. NCI supports a variety of mentored and non-mentored career development award programs designed to foster the transition of new investigators to research independence and to support established investigators in achieving specific objectives. NCI is also committed to building the diversity of the biomedical workforce by supporting candidates from backgrounds nationally underrepresented in cancer research and care.| Due Dates: | Unless otherwise specified in FOA, next due
date is Feb. 08 (OSR) | Feb. 12 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | See specific FOA |
| Eligibility: | Determined from criteria in specific FOA |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Titles & Links: | K99/R00 NIH Pathway to
Independence Award
PA-18-397(Independent
Clinical Trial Required) and
(Independent Clinical Trial Not Allowed)
PA-18-398 K01 NCI Mentored Research Scientist Development Award to Promote Diversity (Clinical Trial Required) PAR-18-365, and (No independent Clinical Trials) PAR-18-364 K08 Mentored Clinical Scientist Research Career Development Award (Independent Clinical Trial Required) PA-18-372, and (No Independent Clinical Trials) PA-18-373 K12 Paul Calabresi Career Development Award for Clinical Oncology (PAR-18-292) Due Date: 6/15/2018 K22 NCI Transition Career Development Award to Promote Diversity (Clinical Trial Required) PAR-18-367, and (No Independent Clinical Trials) PAR-18-366 , The NCI Transition Career Development Award (Independent Clinical Trial Not Allowed) PAR-18-467, and (Independent Clinical Trial Required) PAR-18-466 Also See: Funding for Extramural Cancer Training by the Cancer Training Branch |
NEW
Pre-Announcements
| February 13 (LOI) | All Ranks | Federal | PCOR |
Patient Centered Outcomes Research Institute
Broad PCORI Funding Announcements - Cycle 1 2018 (for
Addressing Disparities, Assessment of Options, Communication and
Dissemination Research)
The Broad PCORI Funding Announcements (PFAs) will seek
investigator-initiated applications for patient-centered
comparative clinical effectiveness research (CER) projects
aligned with the priority areas for research. This PFA
covers the following priority areas:
1. Addressing Disparities (View more information in the pre-announcement)
2. Assessment of Prevention, Diagnosis, and Treatment Options (View more information in the pre-announcement)
3. Communication and Dissemination Research (View more information in the pre-announcement)
Details will be available in the full announcements upon release January 16, 2018.
1. Addressing Disparities (View more information in the pre-announcement)
2. Assessment of Prevention, Diagnosis, and Treatment Options (View more information in the pre-announcement)
3. Communication and Dissemination Research (View more information in the pre-announcement)
Details will be available in the full announcements upon release January 16, 2018.
| Due Dates: | Feb. 13 (Letter of Intent) Full Application: May 14 (OSR) Ι May 16 (Sponsor) |
| Amount & Project Period: | See Announcement |
| Eligibility: | See Announcements for specifics |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Notice of Upcoming PCORI Funding Announcement |
NEW
Pre-Announcements
below
| February 13 (LOI) | All Ranks | Federal | PCOR |
Patient Centered Outcomes Research Institute
Pre-Announcements for 2018 Cycle 1
Please see
Program Funding Announcement (PFA) information below. Final details will become
available on January 16 when full announcements are scheduled for
release.
| Due Dates: | Feb. 13 (Letter of Intent) Full Application: May 14 (OSR) Ι May 16 (Sponsor |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
Dissemination and Implementation of PCORI-Funded Patient-Centered Outcomes Research Results Cycle 1 2018
This limited Program Funding Announcement (PFA) is designed to move evidence developed with PCORI research funding toward practical use in improving health care and health outcomes. PCORI will fund projects that aim to disseminate and implement patient-centered comparative clinical effectiveness research (CER) results obtained from PCORI-funded studies. This limited PFA gives PCORI investigators the opportunity, following the generation of results from their PCORI research award, to propose the next step(s) for making their research results more useful, actionable, accessible, and available to targeted end-users of these findings.| Amount & Project Period: | $350,000 total costs - 2 years |
| Link: | Notice of Upcoming PCORI Dissemination and Implementation Funding Announcement |
Improving Methods for Conducting PCOR - Cycle 1 2018
The purpose is to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by PCOR/CER studies. For the Cycle 1 2018 Methods PFA, PCORI has identified the following Research Areas of Interest (RAIs) as programmatic priorities:1. Methods Related to Ethical and Human Subjects Protections (HSP) Issues in PCOR/CER
2. Methods to Improve Study Design
3. Methods to Support Data Research Networks
4. Methods to Improve the Use of Natural Language Processing
| Amount & Project Period: | $250,000 total costs - 2 years |
| Link: | Notice of Upcoming PCORI Improving Methods Funding Announcement |
Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes - Cycle 1 2018
The purpose is to fund pragmatic clinical trials, large simple trials, or large-scale observational studies comparing 2 or more alternatives for addressing prevention, diagnosis, treatment, or management of a disease or symptom; improving healthcare system-level approaches to managing care; communicating or disseminating research results to patients, caregivers, or clinicians; or eliminating health or healthcare disparities. PCORI's multi-stakeholder panels have identified 16 high-priority topics and research questions. First consideration will be given to applications directly addressing 1 or more of the identified topics, but PCORI is open to receiving and reviewing LOIs for studies on investigator-initiated CER questions as well.| Amount & Project Period: | $250,000 total costs - 2 years |
| Link: | Notice of Upcoming PCORI Pragmatic Clinical Studies Funding Announcement |
| R01 | NCI |
NEW
| February 13 (LOI) | All Ranks | Federal | Diagnostic/Therapeutic Interventions |
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (Clinical Trial Required)
This FOA seeks research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the NCI Division of Cancer Treatment and Diagnosis (DCTD). Applications submitted must include studies that meet the NIH definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA.| Due Dates: | Feb. 13 (Letter of Intent, not required or
binding) Mar. 13 (OSR) Ι Mar. 15 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Limited to < $500,000/Yr. (Direct Costs) - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-560 |
| R01 | NCI |
NEW
| February 13 (LOI) | All Ranks | Federal | Population Science/Clinical Trials |
Cancer Prevention and Control Clinical Trials Grant Program (Clinical Trial Required)
The purpose is to support of investigator-initiated clinical trials having potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, proposed studies should also have potential to improve clinical practice and/or public health. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. Proposed investigator-initiated projects should be related to programmatic interests of NCI's Division of Cancer Prevention and/or Division of Cancer Control and Population Sciences as based on their scientific missions.| Due Dates: | Feb. 13 (Letter of Intent, not required or
binding) Mar. 13 (OSR) Ι Mar. 15 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-559 |
| R01 | NIH |
| February 13 | All Ranks | Federal | Tobacco |
Tobacco Regulatory Science (Clinical Trial Optional)
This FOA seeks applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health.| Due Dates: | Feb. 11 (OSR) Ι Feb. 13 (Sponsor) Additional 2018 Due Date: Jul. 17 |
| Amount & Project Period: | $300,000/yr. (Direct Costs) - 3 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| RFA Link: | RFA-OD-18-002 |
| Companion RFAs: |
RFA-OD-18-003 R21 - Tobacco Regulatory Science (Clinical Trial
Optional) RFA-OD-18-001 R03 - Tobacco Regulatory Science Small Grant Program for New Investigators (Clinical Trial Optional) Note: For purposes of this RFA, a "New Investigator" is defined as a PD/PI who has not yet competed successfully for a substantial, competing NIH independent research award. A list of NIH grants that a PD/PI can hold and still be considered eligible is contained in Section III.1. Eligible Applicants |
| UH2/UH3 | NCI |
| February 14 | All Faculty Ranks | Federal | Assay Validation |
Assay Validation of High Quality Markers for Clinical Studies in Cancer (Clinical Trial Not Allowed)
The purpose is to further optimize and validate molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. It also includes the validation of pharmacodynamic markers and markers of toxicity.The UH2 phase supports analytical validation of assays for these markers that must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this FOA supports clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies.
| Due Dates: | Jan. 14 (Letter of Intent, not required or
binding ) Applications Due: Feb. 12 (OSR) Ι Feb. 14 (Sponsor) Additional 2018 Due Dates: Jul. 10 & Oct. 8 |
| Amount & Project Period: | UH2 - $275,000 (Direct Costs) - 2 years UH3 - $250,000/yr. (Direct Costs) - 3 years |
| Eligibility: | All Faculty Ranks |
| Contact: | Office of Sponsored Research - (x6804) |
| FOA Link: | PAR-18-317 |
| Companion FOA: | PAR-18-310 UH3 |
NEW
| February 15 (LOI) | Junior Faculty | Non-federal | Bone Marrow Disorders |
Aplastic Anemia & MDS International
Foundation (AMDSIF)
2018 Research Grant
The Foundation is interested in funding research across the
spectrum of basic and clinical science, but highest priority is
for studies that have the potential to impact prevention,
diagnosis, risk-stratification, or treatment of these diseases
within three years. Examples include: 1. Discovery of biomarkers predicting response or resistance to existing therapies;
2. Correlative science on patient samples collected from clinical trials, to inform understanding of therapeutic mechanisms;
3. Late-stage pre-clinical research, w/goal of establishing proof-of-concept for a novel therapy;
4. Basic research that reveals new mechanisms of disease likely to benefit patients.
| Due Dates: | February 15 (Letter of Intent) Invited Submissions: Mar. 28 (OSR)|Mar. 30 (Sponsor) |
| Amount & Project Period: | $60,000 - 2 years |
| Eligibility: | Must hold
doctoral-level degree; Preference given to New Investigators proposing a project that will contribute to their professional development in bone marrow failure disease research. New Investigators are post-doctoral fellows, instructors, and those who have been assistant professors < 5 years. No nationality restrictions |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Research Grant Guidelines Ι ProposalCENTRAL |
| R21/R03 | NCI |
NCI R21/R03 Reminder
| February 16 | All Ranks | Federal | See Specific FOA |
National Cancer Institute "R21" and "R03" New/Renewed Funding Opportunity Announcements (FOA)
Listed below are some new and renewed R21 funding opportunities from NCI. There is also a link to a full listing of active R21 and R03 FOAs.| Due Dates: | Feb. 14 (OSR) | Feb. 16 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Generally budgets limited to $275,000 (Direct Costs), and maximum performance period is 2 years. |
| Eligibility: | All Ranks, unless restricted in specific FOA |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Titles and Links: | Using Information Technology to Support
Systematic Screening and Treatment of Depression in Cancer (R21
Clinical Trial Optional)
PA-18-492 Early-life Factors and Cancer Development Later in Life (R21 - Clinical Trial Not Allowed) PA-18-532 Early-life Factors and Cancer Development Later in Life (R03 - Clinical Trial Not Allowed) PA-18-531 See full list at 2018 Program Announcements (PAs) |
| R21 | NIH |
| February 16 | All Ranks | Federal | Obesity |
Exploratory/Developmental Clinical Research Grants in Obesity (Clinical Trial Optional)
This FOA encourages applications for exploratory/developmental clinical studies to accelerate development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children. Exploratory epidemiological research with a goal of informing translational/clinical research will also be supported within this program. (See NCI interests in FOA Part 2, Section I).| Due Dates: | Feb. 14 (OSR) Ι Feb. 16 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | $275,000 (Direct Costs) - 2 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-104 |
| R21 | NCI |
| February 20 | All Ranks | Federal | Clinical/Translational |
NCI Clinical and Translational Exploratory/Developmental Studies (Clinical Trial Optional)
This FOA supports development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials.| Due Dates: | Feb. 16 (OSR) Ι Feb. 20 (Sponsor) Additional 2018 Due Dates: June 19 & Oct. 17 |
| Amount & Project Period: | $275,000 (Direct Costs) - 2 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-020 |
NEW
In partnership with:
| February 20 | Postdocs | Non-federal | Career Development/Immunology |
Society for Immunotherapy of Cancer (SITC)
2018 SITC Fellowship Opportunities
These fellowship awards will help support the development of the
next generation of immunotherapy experts who have a vested
interest in furthering the research and translation of cancer
immunotherapy.| Due Dates: | Feb. 16 (OSR) Ι Feb. 20 (Sponsor) |
| Eligibility: | Current SITC
member; Hold MD, PhD or combined MD/PhD degree; Currently hold position as a postdoctoral fellow, resident, research scientist or comparable position; Be w/in postdoctoral or postgraduate training, or <4 years from completing such training; Commit 75% effort to research supported by the fellowship |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | 2018 SITC Fellowship Opportunities |
SITC-MERCK Cancer Immunotherapy Clinical Fellowship
| Amount & Project Period: | $100,000 -1 year |
SITC-Bristol-Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship
| Amount & Project Period: | $200,000 - 2 years |
SITC-AstraZeneca Postdoctoral Cancer Immunotherapy in Combination Therapies Clinical Fellowship
| Amount & Project Period: | $100,000 - 1 year |
NEW
| February 21 (LOI) | Established Investigators | Non-federal | Bladder Cancer |
Bladder Cancer Advocacy Network (BCAN)
Bladder Cancer Research Innovation Award
Proposed research may be basic, translational, or clinical but must have
direct applicability and relevance to bladder cancer and address
one of these two questions of interest: 1. What are mechanisms by which the resident microbiota interacts with the biology of urothelial cancer?
2. What are the tumor cell autonomous or microenvironmental determinants of bladder cancer progression to metastasis?
Proposals for innovative projects that will develop preliminary data necessary to prepare and submit a competitive research grant application to a major funding agency are encouraged.
| Due Dates: | Feb. 21 (Letter of Intent) Invited Applications: May 14 (OSR) Ι May 16 (Sponsor) |
| Amount & Project Period: | $300,000 - 2 years |
| Eligibility: | Must have a
medical and/or doctoral degree; Must be an independent investigator; Proof of permanent resident status or a valid work visa is required if applicant is not an American or Canadian citizen; May not apply both for this award and for a BCAN Young Investigator Award; Those holding current BCAN Young Investigator Award or Research Innovation Award are not eligible to apply. |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | 2018 Bladder Cancer Research Innovation Award |
NEW
| February 26 | Postdocs & Junior Faculty | Non-federal | Career Development/Bladder Cancer |
Bladder Cancer Advocacy Network (BCAN)
Young Investigator Award and
Patient-Centered Clinical Research Young Investigator Award
These Awards are intended to support development of
outstanding research scientists and clinical cancer research
investigators with a commitment to improving
understanding and treatment of bladder cancer. Projects
must be bladder cancer specific (including upper tract
urothelial carcinoma). For the Young Investigator Award, investigators may be working in basic, translational, clinical, epidemiologic, bioengineering or any other field, but must be working in a research environment capable of supporting transformational bladder cancer research.
For the Patient-Centered Clinical YIA, investigators must be working in a research environment capable of supporting transformational patient-oriented clinical bladder cancer research (e.g. studies of access to care, quality of care, quality of life, health disparities, and patient-centered outcomes research), and a statement regarding applicability of the research to the patient-prioritized BCAN Patient Survey Network (PSN) research questions is required.
| Due Dates: | Feb. 22 (OSR) Ι Feb. 26 (Sponsor) |
| Amount & Project Period: | $50,000 - 1 year |
| Eligibility: | Must be w/in 6 years of completing a
professional degree such as MD, PhD, MD-PhD, MPH, or equivalent or
clinical training such as residency or fellowship; May hold title of Senior Postdoc, Instructor, Research Associate, Assistant Professor or equiv.; At start of grant, applicant cannot hold title of Assoc. Professor; Proof of permanent resident status or valid work visa is required if applicant is not an American or Canadian citizen. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
2018 Young
Investigator Award and
Award Guidelines 2018 Patient-Centered Clinical Research Young Investigator Award and Award Guidelines |
| R03 | NCI |
| February 27 | All Ranks | Federal | Exploratory Research |
NCI Small Grants Program for Cancer Research (NCI Omnibus - Clinical Trial Optional)
This FOA supports small research projects on cancer that can be carried out in a short period of time w/limited resources. An R03 grant supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.| Due Dates: | Feb. 23 (OSR) Ι Feb. 27 (Sponsor) Additional 2018 Due Dates: June 29 & Oct. 26 |
| Amount & Project Period: | $50,000/yr. (Direct Costs) - 2 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-021 |
| U54 | NCI |
| February 27 | Established Investigators | Federal | Health Disparities |
Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (Clinical Trial Optional)
The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity populations and underrepresented students (ISUPSs) and NCI-designated Cancer Centers (CCs). The institutions in each partnership are expected to work collaboratively to: 1) increase the cancer research and cancer research education capacity of the ISUPSs; 2) increase the number of students and investigators from underrepresented populations engaged in cancer research; 3) improve the effectiveness of CCs in developing and sustaining research programs focused on cancer health disparities and increase the number of investigators and students conducting cancer health disparities research; and 4) develop and implement cancer-related activities that benefit the surrounding underserved communities.| Due Dates: | Dec. 13 (Letter of Intent, not required, not
binding) Feb. 23 (OSR) Ι Feb. 27 (Sponsor) Additional Due Dates: January 9, 2019; January 9, 2020 |
| Amount & Project Period: | 2 institutions: Max. $2M/yr. (Direct Costs)
3 institutions: Max. $2.5M/yr. (Direct Costs) Applications exceeding limits will not be accepted. Duration: Max. 5 years |
| Eligibility: | Each partnership
must include both types of institutions: 1) institutions
serving underserved health disparity population and underrepresented
students (ISUPSs); and 2) NCI-designated Cancer Centers (CCs).
(Partnerships involving more than two institutions require NCI approval
before submission of an application.) PD(s)/PI(s) are preferred to be mid-to-senior-level scientists w/records of obtaining grants. A less experienced investigator at an ISUPS can be designated as one of multiple PDs/PIs, if there is an appropriate institutional investment in this investigator, and a demonstrable collaboration (active or planned) of the less experienced investigator with a more experienced PD/PI. The contact PD/PI for the CC must be a CC PD/PI. Both contact PDs/PIs should be reciprocally listed as PD(s)/PI(s) on the linked application from the partner institution. |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-361 |
| R33 | NCI |
| February 28 | All Ranks | Federal | Biospecimen Science |
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 - Clinical Trial Not Allowed)
This FOA supports further development and validation of emerging technologies improving quality of samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during collection, processing, handling, and/or storage of cancer-relevant biospecimens. For these applications, major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community.| Due Dates: | Jan. 30 (Letter of Intent, not required, not
binding) Feb. 26 (OSR) Ι Feb. 28 (Sponsor) Additional 2018 Due Dates: May 29 & Sept. 28 |
| Amount & Project Period: | $300,000/yr. (Direct Costs) - 3 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| RFA Link: | RFA-CA-18-005 |
| Companion RFAs: |
RFA-CA-18-002, R21 (Clinical Trial Not Allowed) RFA-CA-18-003, R33 (Clinical Trial Not Allowed) RFA-CA-18-004, R21 (Clinical Trial Not Allowed) |
NEW
Foundation-facilitated
| February 28 | All Ranks | Non-federal | Cancer Research Projects |
Ocala Royal Dames for Cancer Research, Inc.
Cancer Research
Funding
This RFP funds medical research into finding cures for
cancer. Applications are sought for research that can be
described as translational, pre-clinical - not early bench
work. Proposed projects should be aimed specifically at cancer
and have potential for usefulness in the near future.| Due Dates: | Feb. 28 (Sponsor Receipt Date) |
| Amount & Project Period: | $50,000 (Total Costs) - 2 years |
| Eligibility: | All Ranks |
| Contact: | Suzanne Knapp, Moffitt Foundation (x1400) |
| RFP Link: | RFP for Cancer Research Funding |
NEW
| March 01 | Established Women Investigators | Non-federal | Achievement Award |
Federation of American Societies for Experimental Biology
(FASEB)
2018 Excellence in Science Award
"Recognizing the Research Accomplishments of Women
Scientists"
This award is given in recognition of outstanding achievement by
women in biological science. Recipients are women whose career
achievements have contributed significantly to further
understanding of a particular discipline by excellence in
research.| Due Dates: | Mar. 01 |
| Amount & Project Period: | $10,000 unrestricted research grant and presentation at the annual meeting of a FSAEB Member Society |
| Eligibility: | Nominators and
nominees: must be members of at least one
FASEB Member Society but do not have to be members of the same
society; Award recipient required to present an Excellence in Science Award Lecture at the annual meeting of a FASEB Member Society in the award year; Nominations must be submitted on the Excellence in Science Award nomination form |
| Contact: | Yvette R. Seger, PhD, Director of Science Policy and Staff Liaison to the Excellence in Science Award Committee (301) 634-7124 |
| Link: | FASEB Excellence in Science Award |
| Admin. Supplement | NCI |
NEW
| March 01 | See Below | Federal | PDX/PDXNet |
Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet)(Admin Supp. Clinical Trial Not Allowed)
This FOA is part of the Cancer Moonshot initiative to accelerate cancer research. As part of this initiative, NCI created the Patient-Derived Xenograft (PDX) Development and Trial Centers Research Network (PDXNet) to accelerate development of NCI investigational new drug (IND) agents (i.e., those that NCI is developing in collaboration with pharmaceutical partners) in NCI-sponsored early phase clinical trials. This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-PDXNet investigators and PDXNet investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel therapeutic concepts using the large-scale PDX model collections of PDXNet, and that could ultimately be tested in NCI-sponsored clinical trials.| Due Dates: | Feb. 27 (OSR) Ι Mar. 01 (Sponsor) |
| Amount & Project Period: | No more than $125,000 (total costs) - 1 year and must be w/in currently approved project period for existing parent award. |
| Eligibility: | Requests must be
submitted on paper for the following: P01 Research Program Projects, P30 Center Core Grants, P50 Specialized Center, U54 Specialized Center- Cooperative Agreements, and UM2 Program Project or Center with Complex Structure Cooperative Agreement Requests may be submitted electronically for the following: R01 Research Project Grant, U01 Research Project/Cooperative Agreements, and UM1 Multi-Component Research Project Cooperative Agreements |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-496 |
| K18 | NIH |
| March 06 | All Ranks | Federal | Career Enhancement Award |
Short-term Mentored Career Enhancement Awards for Mid-Career Investigators to Integrate Basic Behavioral and Social Sciences (No Independent Clinical Trials)
This FOA encourages applications for short-term mentored career development (K18) awards that improve synergies among researchers in basic and applied behavioral-social sciences, human subjects and model animals settings; and biomedical and behavioral-social sciences. It is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.| Due Dates: | Mar. 02 (OSR) Ι Mar. 06 (Sponsor) Additional Due Date: Mar. 06, 2019 |
| Amount & Project Period: | May not exceed $100,000 (Total Costs) - 1 year See FOA for specific costs supported |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-349 |
| R21 | NCI |
| March 12 (LOI) | All Ranks | Federal | Cancer Prevention/Control |
Predicting Behavioral Responses to Population-Level Cancer Control Strategies (Clinical Trial Optional)
The goal is to facilitate research to identify individual influences on the effectiveness of population-level strategies that target cancer-related behaviors.| Due Dates: | Mar. 12 (Letter of Intent, not required, not
binding) Apr. 09 (OSR) Ι Apr. 11 (Sponsor) Additional Due Dates: Oct. 10, & Apr. 11, 2019 (w/LOI 30 days prior) |
| Amount & Project Period: | $275,000 (Direct Costs) - 2 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-024 |
| R01 | NCI |
| March 12 (LOI) | All Ranks | Federal | Health Outcomes |
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (Clinical Trial Optional)
This FOA invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.| Due Dates: | Mar. 12 (Letter of Intent, not required, not
binding ) Apr. 09 (OSR) Ι Apr. 11 (Sponsor) Additional Due Dates: Oct. 10, & Apr. 11, 2019 (w/LOI 30 days prior) |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-246 |
| Companion FOA: | PAR-18-247 (R21 Clinical Trial Optional) |
NEW
| March 14 | Junior Faculty | Non-federal | Brain |
The Sontag Foundation
The Distinguished Scientist Award (DSA)
This award provides career and research support to early career
scientists demonstrating outstanding promise for making
scientific and medical breakthroughs in brain cancer research.
Awarded projects will show potential to generate new knowledge
relating to causes, cure or treatment of primary brain
tumors/brain cancer.| Due Dates: | Mar. 12 (OSR) Ι Mar. 14 |
| Amount & Project Period: | $600,000 - 4 years |
| Eligibility: | Must have received first faculty appt. no earlier than March 1, 2013 w/in U. S. or an equiv. institution in Canada. If tenure-granting institution, appt. must be tenure-track. |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | DSA Application Information and Requirements |
NEW
| March 15 | Junior Faculty | Non-federal | Neuromodulation |
AAAS/SCIENCE and Beijing PINS Medical Equipment Co. Ltd.
Science & PINS Prize for Neuromodulation
The Science & PINS Prize for Neuromodulation is a highly competitive prize
which honors scientists for their excellent contributions to
neuromodulation research. | Due Dates: | March 15 (Sponsor) |
| Amount & Project Period: | $25,000 and publication of essay in Science (See link for details) |
| Eligibility: | Must be Junior
Investigator w/advanced degree rec'd. w/in last 10 years,
and must be 45 years or younger as of 01/01/2018; Entrant's essay must describe research and its implications for neuromodulation. Entrant must have performed or directed work described in essay. Research must have been performed during previous 3 years. |
| Contact: | SciencePINSPrize@aaas.org |
| Links: | About the Prize | How to Enter |
| March 15 | Postdocs | Non-federal | Career Development |
Damon Runyon Cancer Research Foundation
Fellowship Awards
This
fellowship award supports all theoretical and experimental
research relevant to the study of cancer and the search for
cancer causes, mechanisms, therapies, and prevention.| Due Dates: | Mar. 13 (OSR) Ι Mar. 15 (Sponsor) Note: This due date is for degrees conferred April 15, 2017 - March 15, 2018, and applicant joined lab on or after April 15, 2017. |
| Amount & Project Period: | $231,000 - 4 years |
| Eligibility: | Applicants must have completed one or more of
the following degrees or its equiv.: (MD, PhD, MD/PhD, DDS, and/or DVM).
See Award Overview/Eligibility for additional details. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Awards Program Information Ι Award Application Guidelines |
NEW
| March 19 | Junior Faculty | Non-federal | Career Development |
Prostate Cancer Foundation
2018 Young Investigator Awards
Research proposals submitted in consideration for this award
should, if successful, provide high impact to the field.
"Small-step" or incremental proposals are usually
non-competitive. Highly innovative basic science programs will
be carefully considered, but priority will be given to "bench to
bedside" translational research proposals w/potential to deliver
near term benefit to patients. Successful applicants should be
working in a research environment capable of supporting
transformational prostate cancer research. Access to and
interaction with a clinical environment and translational
prostate cancer physician-scientists is highly desired.| Due Dates: | Mar. 15 (OSR) | Mar. 19 (Sponsor) |
| Amount & Project Period: | $225,000 - 3 years |
| Eligibility: | S/be w/in 6 years
following completion of a professional degree;
Must hold title of Postdoc, Instructor, Research
Associate, Asst. Professor or equiv.; Must be under direct supervision of a mentor(s) and at least 1 mentor must reside at applicant's institution; S/have received no more than $200,000 in current direct research funding from all sources including institutional funds during the 3-year term of this award |
| Contact: | Office of Sponsored Research (x6804) |
| RFA Link: | RFA |
NEW
| April 01 | All Faculty Ranks | Non-federal | Leukemia |
When Everyone Survives Leukemia Research Foundation
2018 Request for Proposals in Leukemia Research
This RFP solicits innovative research in leukemia and provides support for
laboratory, translational, or clinical research related to acute
leukemia.| Due Dates: | Mar. 28 (OSR) Ι Apr. 01 (Sponsor- Receipt Date) |
| Amount & Project Period: | $50,000 (Total Costs) - 1 year |
| Eligibility: | New and established investigators |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Guidelines |
NEW
| April 01 | All Faculty Ranks | Non-federal | Brain |
B*CURED
2018 Research Investigator Grant Program
Clinical doctors and research scientists whose primary focus is
brain cancer are invited to apply for a grant. Clinical and
translational projects with significant clinical promise will be
considered. Both adult and pediatric brain cancer projects will
be considered.| Due Dates: | Mar. 28 (OSR) Ι Apr. 01 (Sponsor) |
| Amount & Project Period: | $50,000 - 1 year |
| Eligibility: | All Faculty Ranks - must be: Undertaking clinical or translational research, w/intention of applying for R01 NIH funding or equivalent w/in 5 years, or Undertaking innovative research to bridge from bench to animal research or to acquire preclinical data from animal models; Formal involvement of a biostatistician is required for all clinical trial proposals, but not for pre-clinical or translational science proposals. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | 2018 Research Investigator Grant Ι FAQs |
NEW
| April 02 | Postdocs | Non-federal | Immunology/Tumor Immunology |
Cancer Research Institute Irvington
Postdoctoral Fellowship
Program
The Institute seeks hypothesis-driven, mechanistic
studies in both immunology and tumor immunology. Application
must clearly state potential of proposed studies to directly
impact understanding of the immune system's role in cancer risk,
tumor initiation, progression, metastasis, host response to
tumors and/or the treatment of cancer.| Due Dates: | Mar. 29 (OSR) Ι Apr. 02 (Sponsor) Additional 2017 Due Date: Oct. 01 |
| Amount & Project Period: | 3 years Annual Stipend: $55,000, $57,000 & $59,000 Institutional Allowance: $1,500/yr. |
| Eligibility: | Must have
doctoral degree by award activation; Must have < 5 years' postdoc experience; Must have < 3 years' experience in sponsor lab at award activation |
| Contact: | Office of Sponsored Research (x6804) |
| RFA Link: | Program Description Ι Instructions |
| R01 | NCI |
NEW
| April 05 | Small Business Concerns (SBCs) | Federal | Cancer Relevant Technologies |
Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (Clinical Trial Not Allowed)
This FOA invites SBIR grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. Proposed research projects are expected to focus on development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. Applications should specify milestones relevant to both development and commercialization of these technologies. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches.| Due Dates: | April 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Phase I awards: $150,000 - normally not to
exceed 6 mos. Phase II awards: $1,000,000 - normally not to exceed 2 years |
| Eligibility: | Only U.S. small business concerns (SBCs) are
eligible to submit applications (See FOA for details). Primary employment of PD/PI must be w/SBC at the time of award and during conduct of proposed project. For projects with multiple PDs/PIs, at least one must meet primary employment requirement. Occasionally, deviations from this requirement may occur. |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-303 |
NEW
| April 07 | All Faculty Ranks | Non-federal | Lung |
CHEST Foundation
2018 Grant Cycle
Projects supported by the
CHEST Foundation lead to breakthroughs in treatment of chest
diseases and patient care. Higher-level translational research
project is preferred (T1-T5; for definitions, please see:
https://ctsi.mcw.edu/images/CTSI
Translational-Continuum.pdf); basic (cellular or animal)
research projects will not be considered.
| Due Dates: | Apr. 05 (OSR) Ι Apr. 07 (Sponsor- Receipt date) |
| Eligibility: | CHEST membership
required at application; Licensed physicians; Physicians-in-training (residents or fellows), other health-care professionals, or clinical researchers w/relevant experience also be accepted; Special consideration is given to young investigators and applicants in early stages of their careers. |
| Contact: | Office of Sponsored Research (x6804) |
| Primary Link: | Apply for a Grant |
Research Grant in Women's Lung Health
Applications must address important and timely issues surrounding women's lung health, including but not limited to diseases such as COPD and lung cancer.| Amount & Project Period: | $10,000 (Total Costs) - 1 year |
| RFA Link: | Women's Lung Health Guidelines |
Research Grant in Lung Cancer
Applications must address research that leads to improved
medical and/or surgical detection, treatment, and/or cure of
lung cancer. Higher-level translational research project
preferred (T1-T5; for definitions, please see:
https://ctsi.mcw.edu/images/CTSI Translational
Continuum.pdf); basic (cellular or animal) research projects
will not be considered.
| Amount & Project Period: | |
| RFA Link: | Lung Cancer Grant Guidelines |
NEW
Co-sponsored by:
| April 08 | See Below | Non-federal | Career Development |
American Society for Radiation Oncology
ASTRO 2018 Funding
Opportunities
RFAs for the 2018 grant cycle will open on
January 15, 2018. Below is information on the grants available.
Please note that the Full RFAs and submission information will
be available on
proposalCENTRAL on January 15. | Due Dates: | Apr. 05 (OSR) Ι Apr. 08 (Sponsor) |
| Eligibility: | Must have < 5
years in a faculty appointment at time of application, and
be an ASTRO member in good standing; Must attend at least 1 ASTRO Annual Meeting and the BCRF Research Meeting and present findings of this research study at both meetings; At least 50% full-time professional effort must be devoted to goals of award. More details will be contained in RFA |
| Contact: | Office of Sponsored Research (x6804) |
| RFA Link: | ASTRO 2018 Funding Opportunities |
ASTRO-BCRF Career Development Award to End Breast Cancer
Research must be focused on understanding or treatment of breast cancer and include use or impact of radiation treatment.| Amount & Project Period: | $200,000 - 2 years (to be combined with matching funds or in kind contribution from applicant's institution.) |
| RFA Link: | ASTRO-BRCF CDA |
ASTRO-PCF Career Development Award to End Prostate Cancer
Research must be focused on understanding or treatment of prostate cancer and include use or impact of radiation treatment.| Amount & Project Period: | $225,000 - 3 years (to be combined with matching funds or in kind contribution from applicant's institution.) |
| RFA Link: | ASTRO-PCF CDA |
| UG3/UH3 | NCI |
NEW
| April 09 (LOI) | All Ranks | Federal | Cancer Therapy |
Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (Clinical Trial Optional)
This FOA encourages applications to address development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials. The scientific scope includes:1. Development and optimization of QI tools and/or methods for treatment planning, predicting or measuring response to therapy as open source tools that will translate into clinical trial decision support;
2. Validation of the optimized tools in clinical settings to demonstrate their value for decision support in ongoing single-site or multi-site clinical trials.
A phased approach that emphasizes each of these activities must be proposed. Investigators must apply for both the UG3 and UH3 phases together in the single application.
| Due Dates: | Apr. 09 (Letter of Intent, Not required, or
binding) May 07 (OSR) Ι May 09 (Sponsor) Additional 2018 Due Date: Sept.12th |
| Amount & Project Period: | UG Phase: Not to exceed $300,000/yr.
(Direct Costs) - 2 years; UH Phase: Not to exceed $500,000/yr. (Direct Costs) - 3 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-248 |
| Companion FOA: | PAR-18-249 (U01 Clinical Trial Optional) |
NEW
| April 15 | All Ranks | Non-federal | Bridge Funding |
Rivkin Center for Ovarian Cancer
Bridge Funding
Bridge Funding allows researchers to produce data needed to substantiate a
proposal resubmission to federal funding agencies. Interim
funding is provided to researchers who have submitted an R01 or
R21 proposal to the NIH or an original proposal to the
Department of Defense (DoD) pertaining to ovarian cancer, have
not received but were close to, a fundable score.
Investigator-initiated projects in all areas of ovarian cancer
research are eligible. Special consideration will be given to
research that has clinical applicability. .| Due Dates: | Mar. 28 (OSR) Ι Apr. 15 (Sponsor) Additional Due Date: Oct. 15 |
| Amount & Project Period: | $30,000 - (Must have a duration of at least 6 months prior to resubmission to a federal funding agency) |
| Eligibility: | All Ranks Unfunded first submission NIH R01, R21, K08, K23, and K99 proposals (no A1 or A2 proposals) as well as original DoD proposals are eligible. NIH proposals must have scored in the 20th percentile or lower, and DoD proposals must have scored less than 2.5. Must have received agency score w/in past 9 months and must require at least 6 months of additional research prior to resubmission. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Award Guidelines Ι RFA |
Funding Opportunity Calendar
OSR's Grant News
grants.gov
NCI Funding Opportunities
NIH Guide to Grants & Contracts
RaceTracks
Federal Opportunities
Moffitt-Sponsored (Intramural) Opportunities
Opportunities Focused on Thoracic Oncology
Proposal Submission Form
Grants.gov Instructions
PHS398 Instructions
NIH 2590 Instructions
News
NIH Research Matters
The Cancer Letter
NIH News & Events
Federal Register
Science 360 News
PubMed
National Cancer Institute
Clinical Research
Who To Call in Clinical Research
Clinical Research FAQs
Data Safety Monitoring Plan
Liberty IRB
USF IRB
MRISignals@moffitt.org
